SE9901428D0 - Amphibodies - Google Patents
AmphibodiesInfo
- Publication number
- SE9901428D0 SE9901428D0 SE9901428A SE9901428A SE9901428D0 SE 9901428 D0 SE9901428 D0 SE 9901428D0 SE 9901428 A SE9901428 A SE 9901428A SE 9901428 A SE9901428 A SE 9901428A SE 9901428 D0 SE9901428 D0 SE 9901428D0
- Authority
- SE
- Sweden
- Prior art keywords
- amphibody
- cell growth
- nerve cell
- present
- comprised
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9901428A SE9901428D0 (sv) | 1999-04-21 | 1999-04-21 | Amphibodies |
AU46343/00A AU4634300A (en) | 1999-04-21 | 2000-04-20 | Nerve cell growth modulators (amphibodies) |
PCT/SE2000/000764 WO2000064482A1 (en) | 1999-04-21 | 2000-04-20 | Nerve cell growth modulators (amphibodies) |
EP00928054A EP1210120A1 (en) | 1999-04-21 | 2000-04-20 | Nerve cell growth modulators (amphibodies) |
US11/710,541 US20080241157A1 (en) | 1999-04-21 | 2007-02-26 | Nerve cell growth modulators (amphibodies) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9901428A SE9901428D0 (sv) | 1999-04-21 | 1999-04-21 | Amphibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9901428D0 true SE9901428D0 (sv) | 1999-04-21 |
Family
ID=20415301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9901428A SE9901428D0 (sv) | 1999-04-21 | 1999-04-21 | Amphibodies |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080241157A1 (sv) |
EP (1) | EP1210120A1 (sv) |
AU (1) | AU4634300A (sv) |
SE (1) | SE9901428D0 (sv) |
WO (1) | WO2000064482A1 (sv) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8183350B2 (en) | 2002-05-04 | 2012-05-22 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
AU2003265561A1 (en) * | 2002-08-15 | 2004-03-03 | Acorda Therapeutics, Inc. | Chimeric protein |
EP1646353A4 (en) * | 2003-05-16 | 2008-06-04 | Acorda Therapeutics Inc | FUSION PROTEINS FOR THE TREATMENT OF THE CENTRAL NERVOUS SYSTEM |
JP2007532094A (ja) | 2003-05-16 | 2007-11-15 | アコーダ セラピューティクス、インク. | Cns治療用のプロテオグリカン分解変異体 |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
JP4926962B2 (ja) | 2004-05-18 | 2012-05-09 | アコーダ セラピューティクス、インク. | コンドロイチン分解酵素とその安定な製剤の精製法 |
WO2007038548A2 (en) | 2005-09-26 | 2007-04-05 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
CA3086902C (en) | 2006-10-10 | 2021-11-09 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
MX368656B (es) * | 2013-12-20 | 2019-10-10 | Hoffmann La Roche | Métodos mejorados para la producción de polipéptidos recombinantes. |
WO2015091130A1 (en) * | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Method for improving the recombinant production of soluble fusion polypeptides |
CN113999312A (zh) | 2015-06-24 | 2022-02-01 | 豪夫迈·罗氏有限公司 | 具有定制亲和力的抗转铁蛋白受体抗体 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
PE20181004A1 (es) | 2015-10-02 | 2018-06-26 | Hoffmann La Roche | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1341050C (en) * | 1988-11-04 | 2000-07-11 | Martin E. Schwab | Neurite growth regulatory factors |
US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
WO1994017831A1 (en) * | 1993-02-11 | 1994-08-18 | Erziehungsdirektion Of The Canton Zurich | A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration |
EP0724598B1 (en) * | 1993-10-18 | 1999-01-13 | Regeneron Pharmaceuticals, Inc. | Growth factor heterodimers |
WO1995013291A1 (en) * | 1993-11-08 | 1995-05-18 | New York University | Neuron-glia cell adhesion molecule, ng-cam, in treatment of nerve damage |
US7008781B1 (en) * | 1998-12-23 | 2006-03-07 | Regeneron Pharmaceuticals, Inc. | Method of enhancing the biological activity of ligands |
-
1999
- 1999-04-21 SE SE9901428A patent/SE9901428D0/sv unknown
-
2000
- 2000-04-20 WO PCT/SE2000/000764 patent/WO2000064482A1/en active Application Filing
- 2000-04-20 AU AU46343/00A patent/AU4634300A/en not_active Abandoned
- 2000-04-20 EP EP00928054A patent/EP1210120A1/en not_active Ceased
-
2007
- 2007-02-26 US US11/710,541 patent/US20080241157A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU4634300A (en) | 2000-11-10 |
WO2000064482A1 (en) | 2000-11-02 |
EP1210120A1 (en) | 2002-06-05 |
US20080241157A1 (en) | 2008-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9901428D0 (sv) | Amphibodies | |
WO2001016114A3 (en) | Heterocyclic compounds and methods for modulating cxcr3 function | |
WO2002036743A3 (en) | Antisense modulation of calreticulin expression | |
WO2004075865A3 (en) | Selective modulation of tlr-mediated biological activity | |
WO2004007679A3 (en) | Dendritic cell pontentiation | |
PT1017659E (pt) | Tetra-hidronaftalenos substituidos e compostos analogos | |
WO2004005460A3 (en) | Antisense modulation of hmg-coa reductase expression | |
MY124151A (en) | Epothilone derivatives | |
HUP0500634A2 (hu) | Anyagok és eljárások az idegszövet helyreállításának elősegítésére | |
WO2003086280A3 (en) | Immunostimulatory g,u-containing oligoribonucleotides | |
WO2004044181A3 (en) | Antisense modulation of apolipoprotein b expression | |
EP2253706A3 (en) | Antisense modulation of kinesin-like 1 expression | |
AU6589094A (en) | 7-deazapurine modified oligonucleotides | |
TR199700610A3 (tr) | Düsük molekül agirlikli çözünür, tümör nekroz faktörü tip-I ve tip-II proteinleri. | |
WO2004006667A3 (en) | Methods for the regeneration and transformation of cotton | |
WO2001014584A3 (en) | Methods of identifying anti-viral agents | |
WO2004055162A3 (en) | Modulation of endothelial lipase expression | |
WO2003054154A3 (en) | Antisense modulation of mucin 1, transmembrane expression | |
WO2004009024A3 (en) | Modulation of protein kinase c-iota expression | |
WO2000018801A3 (en) | Ncam binding compounds | |
EA200600778A1 (ru) | 1,3-диметилбутилкарбоксанилиды для борьбы с нежелательными микроорганизмами | |
WO2003053341A3 (en) | Antisense modulation of ship-1 expression | |
EP1436308A4 (en) | ANTISENSE MODULATION OF KINASE-4 EXPRESSION ASSOCIATED WITH IL-1 RECEPTOR | |
WO2000040232A3 (en) | Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions | |
WO2003088921A3 (en) | Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression |